Christopher Wilson, PA
Physician Assistant · Destin, FLNPI 1073136784
Payments from drug & device makers
Across 371 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Radius Health, Inc.$596
- Bayer$443
- Xeris Pharmaceuticals, Inc.$369
- Medtronic$368
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,118100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 91 | $1,213 |
| Lilly USA, LLC | 65 | $1,155 |
| Radius Health, Inc. | 45 | $596 |
| Bayer | 26 | $443 |
| Xeris Pharmaceuticals, Inc. | 17 | $369 |
| Medtronic | 19 | $368 |
| Amgen | 24 | $355 |
| Dexcom, Inc. | 9 | $231 |
| Sanofi-aventis U.S. LLC | 14 | $231 |
| Boehringer Ingelheim | 11 | $216 |
| BETA Bionics, Inc. | 11 | $172 |
| Tandem Diabetes Care, Inc. | 7 | $152 |
| AbbVie | 8 | $150 |
| Corcept Therapeutics | 6 | $127 |
| Averitas Pharma Inc. | 5 | $91 |
| Ascendis Pharma Endocrinology Inc | 3 | $62 |
| Recordati_rare_diseases_inc. | 2 | $37 |
| Nevro Corp. | 1 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Novartis | 1 | $16 |
| GRT US Holding, Inc. | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$6,118 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $189,705 |
| MounjaroTirzepatide | 170 | $183,472 |
| TrulicityDulaglutide | 132 | $137,092 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $129,171 |
| JardianceEmpagliflozin | 116 | $121,928 |
| Tresiba Flextouch U-200Insulin Degludec | 76 | $112,118 |
| TymlosAbaloparatide | 28 | $84,900 |
| FarxigaDapagliflozin Propanediol | 26 | $34,818 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $32,197 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $30,412 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $26,184 |
| RybelsusSemaglutide | 23 | $21,970 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $21,794 |
| Humalog Kwikpen U-100Insulin Lispro | 63 | $16,269 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 58 | $15,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,155 | $320,564302 claims |
| Novo NordiskOzempic, Rybelsus | $1,213 | $211,675192 claims |
| Boehringer IngelheimJardiance | $216 | $121,928116 claims |
| Radius Health, Inc.Tymlos | $596 | $84,90028 claims |
| AstraZenecaFarxiga | $16 | $34,81826 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $231 | $13,85814 claims |
| AbbVieSynthroid | $150 | $4,21142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Destin
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
- Ashley MillerGainesville$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.